Platform: Science & Pipeline

Synthetic Biology Platform Developing Targeted Therapeutics 

Human Fat/Lipids Absorption & Digestion

 Oral, Targeted, Non-Systemic Lead 

For decades researches and drug developers have been trying to find a solution for the western's world most growing epidemic: Metabolic Syndrome Diseases, such as Obesity, MASH and Hyperlipidemia. 

MASLD-MASH Metabolic dysfunction-associated steatohepatitis liver disease. Currently, MASLD is a clear unmet need, leaving 100 Million adults in the U.S alone with no treatment. If MASLD is left untreated, it can progress and become a very serious irreversible condition, that will require liver transplant or cause death. 

We engineer enzymes into oral and safe proprietary delivery mechanisms, which allow reduction of lipid accumulation in the blood and in the liver.

Our Nonsystemic therapeutics will be offered as both Mono and Combinational therapies. We strive to help patients reduce levels of toxicity from current therapeutics in the market. Allowing for increased efficacy, better safety profiles and higher tolerability. 

Current GLP1 and Statin therapies are helping millions of patients around the globe. However many many millions of patients are intolerable to these current solutions and are either discontinuing or refusing these or are experiencing sever side effects. 

We work hard to develop safer more tolerable options for all patients, whether on any current therapies or ones that do not have a current tolerable choice. 

As a combination therapy with GLP1 and / or Statins, we are working to provide a solution that targets a completely different MOA. This will bring a potential additive effect to GLP1 / Statins. Our goal is to offer reduced dose of current systemic therapies, without compromising efficacy. 

contact us: lital@purposebio.com